# A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

> **NCT07017777** · PHASE3 · RECRUITING · sponsor: **CanSino Biologics Inc.** · enrollment: 600 (estimated)

## Conditions studied

- Pneumococcal Infections
- Streptococcal Infections
- Bacterial Infections

## Interventions

- **BIOLOGICAL:** PCV13i
- **BIOLOGICAL:** Prevnar 13

## Key facts

- **NCT ID:** NCT07017777
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-14
- **Primary completion:** 2027-02-15
- **Final completion:** 2028-05-15
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017777, "A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07017777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*